AXOGEN, INC.
In the published model solve dated 2026-Q2, anchored at $39.49, AXOGEN, INC. (AXGN) is priced for today's economics sustained for ~8.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Avance became the first FDA-approved biologic for repairing gaps in peripheral nerves in December 2025, carrying twelve years of market exclusivity [Source: Axogen press release, December 3, 2025], which turns a product previously sold under tissue rules into one competitors cannot simply copy. • That approval came through the accelerated pathway, and the 10-K is explicit that the indications ⟦"were granted under the FDA's accelerated approval program, and continued approval for these indicati
Is AXGN overvalued? See what's priced in →
212 institutional managers reported holding AXGN in 13F filings for the quarter ended 2026-03-31. 41 opened new positions that quarter. Held by BlackRock, Vanguard Group, Morgan Stanley, among others. On the short side, 3.7M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AXGN's share count grew 25.6% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at AXGN over the trailing three years: 2023: 3 buys totaling $189k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AXGN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -20.8% | -36.4% |
| 2023-11-08 | +37.4% | +52.2% |
| 2024-03-06 | -14.4% | -35.2% |
| 2024-05-03 | -11.7% | +30.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AXGN's latest 8-K filings: 2026-06-23 (items 5.07); 2026-04-28 (items 2.02, 7.01, 9.01); 2026-02-24 (items 2.02, 7.01, 9.01); 2026-01-23 (items 1.01, 8.01, 9.01); 2026-01-12 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.